These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 23620818

  • 1. PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.
    Hulsmans M, Geeraert B, Arnould T, Tsatsanis C, Holvoet P.
    PLoS One; 2013; 8(4):e62253. PubMed ID: 23620818
    [Abstract] [Full Text] [Related]

  • 2. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination.
    Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T.
    Diabetes; 2005 Dec; 54(12):3358-70. PubMed ID: 16306350
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
    Massaro M, Scoditti E, Pellegrino M, Carluccio MA, Calabriso N, Wabitsch M, Storelli C, Wright M, De Caterina R.
    Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
    [Abstract] [Full Text] [Related]

  • 4. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A, Otto K, Hawkins E, Barr R, Bensch WR, Bull C, Dana S, Klausing K, Martin JA, Rafaeloff-Phail R, Rafizadeh-Montrose C, Rhodes G, Robey R, Rojo I, Rungta D, Snyder D, Wilbur K, Zhang T, Zink R, Warshawsky A, Brozinick JT.
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [Abstract] [Full Text] [Related]

  • 5. Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism.
    Dallaire P, Bellmann K, Laplante M, Gélinas S, Centeno-Baez C, Penfornis P, Peyot ML, Latour MG, Lamontagne J, Trujillo ME, Scherer PE, Prentki M, Deshaies Y, Marette A.
    Diabetes; 2008 Aug; 57(8):1999-2011. PubMed ID: 18458147
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
    Hiuge-Shimizu A, Maeda N, Hirata A, Nakatsuji H, Nakamura K, Okuno A, Kihara S, Funahashi T, Shimomura I.
    Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):792-9. PubMed ID: 21233451
    [Abstract] [Full Text] [Related]

  • 8. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.
    Fernandes-Santos C, Carneiro RE, de Souza Mendonca L, Aguila MB, Mandarim-de-Lacerda CA.
    Nutrition; 2009 Apr; 25(7-8):818-27. PubMed ID: 19268533
    [Abstract] [Full Text] [Related]

  • 9. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
    Choi WS, Lee JJ, Kim Y, Kim IS, Zhang WY, Myung CS.
    Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
    [Abstract] [Full Text] [Related]

  • 10. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
    Abd El-Haleim EA, Bahgat AK, Saleh S.
    Eur J Pharmacol; 2016 Feb 15; 773():59-70. PubMed ID: 26825546
    [Abstract] [Full Text] [Related]

  • 11. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
    Hennuyer N, Tailleux A, Torpier G, Mezdour H, Fruchart JC, Staels B, Fiévet C.
    Arterioscler Thromb Vasc Biol; 2005 Sep 15; 25(9):1897-902. PubMed ID: 15994444
    [Abstract] [Full Text] [Related]

  • 12. Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.
    Barbieri M, Di Filippo C, Esposito A, Marfella R, Rizzo MR, D'Amico M, Ferraraccio F, Di Ronza C, Duan SZ, Mortensen RM, Rossi F, Paolisso G.
    PLoS One; 2012 Sep 15; 7(4):e35999. PubMed ID: 22563432
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.
    Srivastava RA.
    Atherosclerosis; 2011 Jan 15; 214(1):86-93. PubMed ID: 21093860
    [Abstract] [Full Text] [Related]

  • 16. Effect of peroxisome proliferator-activated receptor-alpha ligands in the interaction between adipocytes and macrophages in obese adipose tissue.
    Toyoda T, Kamei Y, Kato H, Sugita S, Takeya M, Suganami T, Ogawa Y.
    Obesity (Silver Spring); 2008 Jun 15; 16(6):1199-207. PubMed ID: 18356826
    [Abstract] [Full Text] [Related]

  • 17. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.
    Haluzik MM, Lacinova Z, Dolinkova M, Haluzikova D, Housa D, Horinek A, Vernerova Z, Kumstyrova T, Haluzik M.
    Endocrinology; 2006 Sep 15; 147(9):4517-24. PubMed ID: 16740970
    [Abstract] [Full Text] [Related]

  • 18. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
    Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH, Choi KM.
    Biochem Biophys Res Commun; 2005 Oct 28; 336(3):747-53. PubMed ID: 16157299
    [Abstract] [Full Text] [Related]

  • 19. The peroxisome proliferator activated receptor gamma (PPARgamma) ligand rosiglitazone modulates bronchoalveolar lavage levels of leptin, adiponectin, and inflammatory cytokines in lean and obese mice.
    Holguin F, Rojas M, Hart CM.
    Lung; 2007 Dec 28; 185(6):367-72. PubMed ID: 17909895
    [Abstract] [Full Text] [Related]

  • 20. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN, Tao RY, Tian JY, Liu GT, Ye F.
    Life Sci; 2008 May 07; 82(19-20):983-90. PubMed ID: 18417155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.